. 2007 Dec;14(Suppl 1):S3–S10. doi: 10.3747/co.2007.153

TABLE II.

Disease-free survival in the Arimidex, ^a Tamoxifen, Alone or in Combination trial, patients with hormone receptor–positive tumours ²⁰

Comparison	Follow-up
	33 Months¹⁷			47 Months¹⁸			68 Months¹⁶
	hr ^b	95% ci	p Value	hr ^b	95% ci	p Value	hr ^b	95% ci	p Value
Anastrozole vs. tamoxifen	0.78	0.65 to 0.93	0.003	0.82	0.70 to 0.96	0.014	0.83	0.73 to 0.94	0.005
Anastrozole vs. combination	0.76	0.63 to 0.91	0.002	nr			Combination therapy discontinued

AstraZeneca Canada, Mississauga, ON (generic name: anastrozole).

Hazard ratios shown in bold type are statistically significant.

hr = hazard ratio; ci = confidence interval; nr = not reported.